257 related articles for article (PubMed ID: 26320076)
1. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.
Takahashi Y; Iwaya T; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Takano Y; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K
Ann Surg Oncol; 2014 Jan; 21(1):205-12. PubMed ID: 24046120
[TBL] [Abstract][Full Text] [Related]
3. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
[TBL] [Abstract][Full Text] [Related]
4. NIMA related kinase 2 promotes gastric cancer cell proliferation
Fan WD; Chen T; Liu PJ
World J Gastroenterol; 2019 Jun; 25(23):2898-2910. PubMed ID: 31249448
[TBL] [Abstract][Full Text] [Related]
5. Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis.
Fu L; Liu S; Wang H; Ma Y; Li L; He X; Mou X; Tong X; Hu Z; Ru G
Cancer Biomark; 2017 Jul; 20(1):101-106. PubMed ID: 28759960
[TBL] [Abstract][Full Text] [Related]
6. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.
Hayward DG; Clarke RB; Faragher AJ; Pillai MR; Hagan IM; Fry AM
Cancer Res; 2004 Oct; 64(20):7370-6. PubMed ID: 15492258
[TBL] [Abstract][Full Text] [Related]
7. MiR-1299 functions as a tumor suppressor to inhibit the proliferation and metastasis of prostate cancer by targeting NEK2.
Zhang FB; Du Y; Tian Y; Ji ZG; Yang PQ
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):530-538. PubMed ID: 30720160
[TBL] [Abstract][Full Text] [Related]
8. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.
Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW
Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664
[TBL] [Abstract][Full Text] [Related]
9. Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer.
Xu T; Zeng Y; Shi L; Yang Q; Chen Y; Wu G; Li G; Xu S
J Exp Clin Cancer Res; 2020 Sep; 39(1):183. PubMed ID: 32907622
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
11. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
Lee J; Gollahon L
Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
13. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
[TBL] [Abstract][Full Text] [Related]
14. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
Marina M; Saavedra HI
Front Biosci (Landmark Ed); 2014 Jan; 19(2):352-65. PubMed ID: 24389189
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance and prognostic value of Nek2 protein expression in colon cancer.
Lu L; Zhai X; Yuan R
Int J Clin Exp Pathol; 2015; 8(11):15467-73. PubMed ID: 26823916
[TBL] [Abstract][Full Text] [Related]
16. Nek2 kinase in chromosome instability and cancer.
Hayward DG; Fry AM
Cancer Lett; 2006 Jun; 237(2):155-66. PubMed ID: 16084011
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival.
Neal CP; Fry AM; Moreman C; McGregor A; Garcea G; Berry DP; Manson MM
J Surg Oncol; 2014 Dec; 110(7):828-38. PubMed ID: 25043295
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.
Liu H; Liu B; Hou X; Pang B; Guo P; Jiang W; Ding Q; Zhang R; Xin T; Guo H; Xu S; Pang Q
J Neurooncol; 2017 May; 132(3):409-417. PubMed ID: 28321704
[TBL] [Abstract][Full Text] [Related]
19. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.
Ning Z; Wang A; Liang J; Liu J; Zhou T; Yan Q; Wang Z
Int J Clin Exp Pathol; 2014; 7(5):2462-9. PubMed ID: 24966957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
